Nautilus Biotechnology, Inc.: PERCEPTIVE ADVISORS LLC amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Perceptive Advisors LLC amended its Schedule 13D stake filing for Nautilus Biotechnology, Inc., according to SEC accession 0001193125-26-445289. The filing updates the investor's previously reported beneficial ownership position in the protein-analysis company. Schedule 13D amendments are required when a holder's ownership or intent changes materially, making the disclosure a signal of activist or strategic interest. The exact revised share count and percentage were not specified in the headline. Investors will watch for further 13D amendments or Form 4 insider filings to gauge whether Perceptive is adding to or trimming its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Perceptive Advisors LLC, Nautilus Biotechnology, Inc.